LGALS3 and type 2 diabetes mellitus: Galectin-3 levels were 10.6 ± 3.7 ng/mL in obese controls without CVD and 13.8 ± 3.3 ng/mL in T2DM patients (p = 0.164 for obese controls without CVD vs. T2DM), and highest in HFpEF patients with T2DM (16.1 ± 3.8 ng/mL), the only significant difference of which was reached when HFpEF with T2DM was compared to obese controls without CVD (p = 0.011, with p = 0.226 for HFpEF with T2DM vs. T2DM).